BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25916298)

  • 1. [Construction of CD19-CAR retroviral vector and modification of its transduction of human T-lymphocytes].
    Wang Y; Tang G; Xu L; Ruan J; Cheng H; Zhou H; Hua Y; Hu X; Gu H; Qian B; Wang J; Yang J
    Zhonghua Xue Ye Xue Za Zhi; 2015 Apr; 36(4):331-6. PubMed ID: 25916298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Feldman SA; Zhao Y; Xu H; Black MA; Morgan RA; Wilson WH; Rosenberg SA
    J Immunother; 2009 Sep; 32(7):689-702. PubMed ID: 19561539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Construction and in vitro verification of a new humanized anti-CD19 CAR-T cells with high affinity].
    Zhang CX; Cheng H; Han X; Qi KM; Chen W; Wu QY; Cao J; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):465-470. PubMed ID: 30032561
    [No Abstract]   [Full Text] [Related]  

  • 4. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
    Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
    Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.
    Sakemura R; Terakura S; Watanabe K; Julamanee J; Takagi E; Miyao K; Koyama D; Goto T; Hanajiri R; Nishida T; Murata M; Kiyoi H
    Cancer Immunol Res; 2016 Aug; 4(8):658-68. PubMed ID: 27329987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
    Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Construction and application of retroviral vector system useful for high-efficiency transfection into human T cells].
    Zhang RP; Yun L; Peng L; Lu B; Zhou Q; Wang H; Guo YJ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jul; 22(4):420-2, 426. PubMed ID: 16805997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors.
    De Oliveira SN; Wang J; Ryan C; Morrison SL; Kohn DB; Hollis RP
    J Transl Med; 2013 Jan; 11():23. PubMed ID: 23360526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly efficient gene transfer into antigen-specific primary mouse lymphocytes with replication-deficient retrovirus expressing the 10A1 envelope protein.
    Annenkov AE; Daly GM; Chernajovsky Y
    J Gene Med; 2002; 4(2):133-40. PubMed ID: 11933214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of signal peptide optimized by site-directed mutagenesis on the function of chimeric antigen receptor T cells].
    Liu Y; Li F; Dai H; Zhou R; Wang M; Gan S; Xu Y
    Sheng Wu Gong Cheng Xue Bao; 2024 Feb; 40(2):573-584. PubMed ID: 38369842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Modification of Tumor-Infiltrating Lymphocytes
    Weinstein-Marom H; Gross G; Levi M; Brayer H; Schachter J; Itzhaki O; Besser MJ
    Front Immunol; 2020; 11():584148. PubMed ID: 33488585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An experimental study of CD4 targeted chimeric antigen receptor modified T cell with anti-lymphoma activity].
    Chen GH; Huang HW; Wang Y; Liu HW; Xu LJ; Ma X; Xue SL; He XF; Wang Y; Gu B; Li CX; Qiu HY; Tang XW; Jin ZM; Miao M; Sun AN; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2018 Feb; 39(2):148-152. PubMed ID: 29562451
    [No Abstract]   [Full Text] [Related]  

  • 18. [Optimization of CAR-T cell culture system and lentivirus transduction conditions].
    Wang H; Pan J; Jiang D; Qu Y; Li Y; Li G; Chu Y; Zhang X; Xu G
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 May; 36(5):390-397. PubMed ID: 32696750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.
    Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.
    Farson D; McGuinness R; Dull T; Limoli K; Lazar R; Jalali S; Reddy S; Pennathur-Das R; Broad D; Finer M
    J Gene Med; 1999; 1(3):195-209. PubMed ID: 10738568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.